South San Francisco Newswire

South San Francisco Newswire

Comprehensive Real-Time News Feed for South San Francisco, CA.

Results 1 - 20 of 87 for "u:americanbankingnews.com" in South San Francisco, CA

  1. Recent Research Analysts' Ratings Changes for Portola PharmaceuticalsRead the original story w/Photo

    6 hrs ago | AmericanBankingNews.com

    1/15/2018 - Portola Pharmaceuticals was given a new $80.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a "buy" rating on the stock.

    Comment?

  2. Portola Pharmaceuticals (PTLA) Rating Lowered to Sell at Zacks Investment ResearchRead the original story w/Photo

    Sunday Jan 7 | AmericanBankingNews.com

    According to Zacks, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.

    Comment?

  3. Portola Pharmaceuticals (PTLA) - Investment Analysts' Weekly Ratings ChangesRead the original story w/Photo

    Thursday Jan 4 | AmericanBankingNews.com

    According to Zacks, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.

    Comment?

  4. Analysts' Downgrades for January, 2nd (CALA, CATB, CATM, CAVM,...Read the original story w/Photo

    Tuesday Jan 2 | AmericanBankingNews.com

    According to Zacks, "Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.

    Comment?

  5. Calithera Biosciences (CALA) Downgraded by Zacks Investment Research to "Hold"Read the original story w/Photo

    Tuesday Jan 2 | AmericanBankingNews.com

    According to Zacks, "Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.

    Comment?

  6. Catalyst Biosciences (CBIO) Rating Increased to Buy at Zacks Investment ResearchRead the original story w/Photo

    Tuesday Jan 2 | AmericanBankingNews.com

    The firm currently has a $15.00 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price objective suggests a potential upside of 4.38% from the company's previous close.

    Comment?

  7. Zacks Investment Research Lowers Catalyst Biosciences (CBIO) to HoldRead the original story w/Photo

    Monday Jan 1 | AmericanBankingNews.com

    According to Zacks, "Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa.

    Comment?

  8. Global Blood Therapeutics (GBT) - Analysts' Weekly Ratings ChangesRead the original story w/Photo

    Friday Dec 22 | AmericanBankingNews.com

    Several brokerages have updated their recommendations and price targets on shares of Global Blood Therapeutics in the last few weeks: 12/20/2017 - Global Blood Therapeutics was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 12/15/2017 - Global Blood Therapeutics had its "outperform" rating reaffirmed by analysts at Wedbush.

    Comment?

  9. Recent Analysts' Ratings Changes for Global Blood TherapeuticsRead the original story w/Photo

    Dec 7, 2017 | AmericanBankingNews.com

    According to Zacks, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial.

    Comment?

  10. Research Analysts' Upgrades for December, 6th (ADES, ANDV,...Read the original story w/Photo

    Dec 6, 2017 | AmericanBankingNews.com

    They currently have $66.00 price target on the stock. According to Zacks, "Foundation Medicine, Inc. provides molecular information products primarily in the United States.

    Comment?

  11. Global Blood Therapeutics (GBT) Upgraded at Zacks Investment ResearchRead the original story w/Photo

    Dec 6, 2017 | AmericanBankingNews.com

    According to Zacks, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial.

    Comment?

  12. Denali Therapeutics Plans $149 Million IPO for December 8thRead the original story w/Photo

    Nov 29, 2017 | AmericanBankingNews.com

    Denali Therapeutics plans to raise $149 million in an initial public offering on Friday, December 8th, IPO Scoop reports. The company will issue 8,300,000 shares at a price of $17.00-$19.00 per share.

    Comment?

  13. Global Blood Therapeutics (GBT) - Investment Analysts' Weekly Ratings UpdatesRead the original story w/Photo

    Nov 24, 2017 | AmericanBankingNews.com

    A number of firms have modified their ratings and price targets on shares of Global Blood Therapeutics recently: 11/13/2017 - Global Blood Therapeutics was given a new $53.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a "buy" rating on the stock.

    Comment?

  14. Recent Analysts' Ratings Changes for AchaogenRead the original story w/Photo

    Nov 23, 2017 | AmericanBankingNews.com

    According to Zacks, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections.

    Comment?

  15. Weekly Investment Analysts' Ratings Changes for VeracyteRead the original story w/Photo

    Nov 22, 2017 | AmericanBankingNews.com

    They now have a "buy" rating on the stock. 11/10/2017 - Veracyte was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.

    Comment?

  16. Research Analysts' Downgrades for November, 14th (ADDYY, AKAO,...Read the original story w/Photo

    Nov 14, 2017 | AmericanBankingNews.com

    According to Zacks, "Adidas is a leading brand in the sporting goods market with strong positions in footwear, apparel and hardware. Adidas products offer technological innovations and cutting-edge designs to athletes of all skill levels who aspire to achieve peak performance.

    Comment?

  17. Achaogen, Inc. (AKAO) Cut to Sell at Zacks Investment ResearchRead the original story w/Photo

    Nov 14, 2017 | AmericanBankingNews.com

    According to Zacks, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections.

    Comment?

  18. Zacks Investment Research Downgrades CytomX Therapeutics, Inc. (CTMX) to HoldRead the original story w/Photo

    Nov 10, 2017 | AmericanBankingNews.com

    According to Zacks, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody therapeutics for the treatment of cancer.

    Comment?

  19. Global Blood Therapeutics (GBT) - Investment Analysts' Weekly Ratings ChangesRead the original story w/Photo

    Nov 9, 2017 | AmericanBankingNews.com

    According to Zacks, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial.

    Comment?

  20. Calithera Biosciences, Inc. (CALA) Upgraded to Buy at Zacks Investment ResearchRead the original story w/Photo

    Nov 6, 2017 | AmericanBankingNews.com

    The firm currently has a $19.00 target price on the biotechnology company's stock. Zacks Investment Research 's price objective would suggest a potential upside of 14.11% from the company's previous close.

    Comment?

South San Francisco Job Listings
View or post South San Francisco job listings on Topix.
South San Francisco Real Estate
News, listings, and foreclosures in South San Francisco from Topix.
South San Francisco Mortgages
Find mortgage rates in South San Francisco on Topix.